Department of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
The Miriam Hospital and Alpert School of Medicine at Brown University, Weight Control and Diabetes Research Center, Providence, RI, USA.
Int J Obes (Lond). 2022 Aug;46(8):1556-1559. doi: 10.1038/s41366-022-01131-1. Epub 2022 May 2.
Young adulthood is often a period of substantial weight gain increasing risk for obesity and cardiometabolic disease. Uric acid (UA), a clinical marker of oxidative stress, is associated with cardiometabolic dysfunction in established CVD, type 2 diabetes, and CKD. Yet, few trials have examined UA as a predictor of cardiometabolic risk in young, healthy populations, particularly in the context of weight gain prevention intervention. The purpose of this ancillary study was to examine UA in the Study of Novel Approaches to Weight Gain Prevention (SNAP), a randomized, controlled trial of weight gain prevention strategies in young healthy adults. UA was examined as a predictor of weight and cardiometabolic outcomes over 6 years; the impact of weight gain prevention interventions on UA was also examined. We found that higher baseline UA was a significant predictor of less favorable BMI, triglycerides, HDL, glucose, insulin, and HOMA, independent of age, sex, baseline weight, baseline level of the outcome variable, and weight gain prevention intervention. Additionally, ≥1% weight loss was associated with lower UA. UA is a promising biomarker for future weight gain and cardiometabolic risk in young adults that may respond to weight gain prevention.Clinical trial registration: clinicaltrials.gov identifier NCT01183689.
青年期通常是体重显著增加的时期，这增加了肥胖和心血管代谢疾病的风险。尿酸（UA）是氧化应激的临床标志物，与已确立的心血管疾病、2 型糖尿病和 CKD 中的心血管代谢功能障碍有关。然而，很少有试验研究 UA 作为年轻健康人群中心血管代谢风险的预测因子，尤其是在预防体重增加干预的背景下。本辅助研究的目的是在体重增加预防研究（SNAP）中检查 UA，这是一项针对年轻健康成年人的体重增加预防策略的随机对照试验。UA 被作为 6 年内体重和心血管代谢结果的预测因子进行了研究；还研究了体重增加预防干预对 UA 的影响。我们发现，较高的基线 UA 是 BMI、甘油三酯、HDL、葡萄糖、胰岛素和 HOMA 更不利的显著预测因子，独立于年龄、性别、基线体重、基线结果变量水平和体重增加预防干预。此外，体重减轻≥1%与 UA 降低有关。UA 是年轻成年人未来体重增加和心血管代谢风险的有前途的生物标志物，可能对体重增加预防有反应。临床试验注册：clinicaltrials.gov 标识符 NCT01183689。
